CA2537057A1 - Cancer treatment with epothilones - Google Patents

Cancer treatment with epothilones Download PDF

Info

Publication number
CA2537057A1
CA2537057A1 CA002537057A CA2537057A CA2537057A1 CA 2537057 A1 CA2537057 A1 CA 2537057A1 CA 002537057 A CA002537057 A CA 002537057A CA 2537057 A CA2537057 A CA 2537057A CA 2537057 A1 CA2537057 A1 CA 2537057A1
Authority
CA
Canada
Prior art keywords
treatment
pharmaceutical preparation
epothilone
proliferative disease
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002537057A
Other languages
English (en)
French (fr)
Inventor
Clifford Dilea
Paul M. J. Mcsheehy
Sauveur-Michel Maira
Chiaki Tanaka
Markus Wartmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2537057A1 publication Critical patent/CA2537057A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002537057A 2003-09-02 2004-09-01 Cancer treatment with epothilones Abandoned CA2537057A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49954803P 2003-09-02 2003-09-02
US60/499,548 2003-09-02
PCT/EP2004/009737 WO2005020989A1 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Publications (1)

Publication Number Publication Date
CA2537057A1 true CA2537057A1 (en) 2005-03-10

Family

ID=34272839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002537057A Abandoned CA2537057A1 (en) 2003-09-02 2004-09-01 Cancer treatment with epothilones

Country Status (9)

Country Link
US (2) US20060235059A1 (cg-RX-API-DMAC7.html)
EP (1) EP1663214A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007504259A (cg-RX-API-DMAC7.html)
CN (1) CN1870995A (cg-RX-API-DMAC7.html)
AU (1) AU2004268377B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414043A (cg-RX-API-DMAC7.html)
CA (1) CA2537057A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06002393A (cg-RX-API-DMAC7.html)
WO (1) WO2005020989A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
CN102811743B (zh) 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
EP2512459A4 (en) * 2009-12-15 2013-08-07 THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME
HUE043998T2 (hu) 2012-09-17 2019-09-30 Pfizer Eljárás terápiás nanorészecskék elõállítására
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
DE60225666T2 (de) * 2001-01-25 2009-04-16 Bristol-Myers Squibb Co. Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
AU2003296878A1 (en) * 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
ES2297189T3 (es) * 2002-08-02 2008-05-01 Novartis Ag Derivados de epotilona.
CA2510610A1 (en) * 2002-12-09 2004-06-24 Novartis Ag Microtubule stabilisers for treating stenosis in stents
EP1641449A1 (en) * 2003-06-27 2006-04-05 Novartis AG Cancer treatment with epothilones

Also Published As

Publication number Publication date
US20060235059A1 (en) 2006-10-19
US20090069394A1 (en) 2009-03-12
CN1870995A (zh) 2006-11-29
BRPI0414043A (pt) 2006-10-24
AU2004268377B2 (en) 2008-06-26
MXPA06002393A (es) 2006-06-20
EP1663214A1 (en) 2006-06-07
JP2007504259A (ja) 2007-03-01
WO2005020989A1 (en) 2005-03-10
AU2004268377A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
US20090069394A1 (en) Cancer treatment with epothilones
AU755944B2 (en) Use of epothilones for the treatment of cancer
US6302838B1 (en) Cancer treatment with epothilones
EP1052974B1 (en) Pharmaceutical formulation containing epothilone
JP2002504511A5 (cg-RX-API-DMAC7.html)
US20170232017A1 (en) Treatment of cancer
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
AU2004251444B2 (en) Cancer treatment with epothilones
RU2242229C2 (ru) Применение эпотилонов для лечения рака
AU2003202508B2 (en) Use of epothilones for the treatment of cancer
WO2019106424A1 (en) Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas
ES2354193T3 (es) Utilización de epotilonas para el tratamiento del cáncer.
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
HK1033809B (en) Pharmaceutical formulation containing epothilone
HK1073601B (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued